Please login to the form below
cemiplimab
This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). ... The multicentre, non-randomised
Latest news
-
Merck’s Keytruda improves outcomes for metastatic cervical cancer patients
In March, Sanofi and Regeneron revealed positive data for their PD-1 inhibitor Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
-
Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients
The phase 3 trial had been investigating Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic. ... Specifically, Libtayo (cemiplimab-rwlc) was cleared for use in newly-diagnosed,
-
Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US
Specifically, Libtayo (cemiplimab-rwlc) has been cleared for use in newly-diagnosed, locally-advanced or metastatic NSCLC patients who have high PD-L1 tumour expression and are not candidates for surgery
-
Sanofi reports a profit in Q4 as Dupixent sales climb
Oncology sales were also up in Q4 2020, growing 24.6% to 213m – driven primarily by new launches of multiple myeloma treatment Sarclisa (isatuximab) and skin cancer therapy Libtayo (cemiplimab).
-
In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa
Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a
More from news
Approximately 3 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Regeneron and Bluebird sign $100m cell therapies deal
Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
